Literature DB >> 10975549

Thymoma.

H K Müller-Hermelink1, A Marx.   

Abstract

Thymomas are fascinating tumors because of their multifaceted clinical presentation, including an unrivaled frequency of associated paraneoplastic autoimmune diseases and an astounding histologic heterogeneity. Thus, thymomas challenge the clinician, pathologist, and immunologist alike with complex diagnostic and therapeutic problems in almost all fields of medicine, radiology, nuclear medicine, surgery, radiooncology, and pathology. This review highlights recent progress in these fields, including the new World Health Organization's classification of thymomas, and reports on the beginning discovery of the genetic basis of thymoma oncogenesis and the cellular and molecular immunopathology of thymoma-associated paraneoplastic autoimmunity.

Entities:  

Mesh:

Year:  2000        PMID: 10975549     DOI: 10.1097/00001622-200009000-00007

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  23 in total

1.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Francesca Ciaraffa; Giovanni Scambia; Amelia Evoli
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

3.  Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab.

Authors:  Ahmad I Antar; Zaher K Otrock; Mohamed A Kharfan-Dabaja; Rami A Mahfouz; Raafat S Alameddine; Nadim M W El-Majzoub; Ziad M Salem
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-11       Impact factor: 0.900

4.  Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall.

Authors:  Patrick Adam; Samy Hakroush; Ilse Hofmann; Sonja Reidenbach; Alexander Marx; Philipp Ströbel
Journal:  Virchows Arch       Date:  2014-06-13       Impact factor: 4.064

5.  Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect.

Authors:  Mickie H Cheng; Una Fan; Navdeep Grewal; Michael Barnes; Anand Mehta; Steve Taylor; Eystein S Husebye; Elizabeth J Murphy; Mark S Anderson
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

6.  A novel animal model of thymic tumour: development of epithelial thymoma in transgenic rats carrying human T lymphocyte virus type I pX gene.

Authors:  Kazunori Kikuchi; Hitoshi Ikeda; Takahiro Tsuchikawa; Takahiro Tsuji; Satoshi Tanaka; Kazunori Fugo; Toshiaki Sugaya; Yuetsu Tanaka; Masatoshi Tateno; Naoki Maruyama; Takashi Yoshiki
Journal:  Int J Exp Pathol       Date:  2002-10       Impact factor: 1.925

7.  Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.

Authors:  Yukari Miki; Kana Hamada; Tadashi Yoshino; Katsuya Miyatani; Kiyoshi Takahashi
Journal:  Virchows Arch       Date:  2014-05-07       Impact factor: 4.064

8.  Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia.

Authors:  Tetsuro Araki; Lynette M Sholl; Victor H Gerbaudo; Hiroto Hatabu; Mizuki Nishino
Journal:  AJR Am J Roentgenol       Date:  2014-03       Impact factor: 3.959

9.  Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Giacomo Minicuci; Raffaella Riso; Laura Peri; Giovanni Scambia; Amelia Evoli
Journal:  J Clin Immunol       Date:  2007-11-14       Impact factor: 8.317

10.  Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas.

Authors:  S Scarpino; A Di Napoli; A Stoppacciaro; M Antonelli; E Pilozzi; R Chiarle; G Palestro; M Marino; F Facciolo; E A Rendina; K E Webster; S A Kinkel; H S Scott; L Ruco
Journal:  Clin Exp Immunol       Date:  2007-06-22       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.